IntegriChain Acquires Blue Fin Group

IntegriChain, delivering Life Sciences’ only comprehensive data and business process platform for market access, announced Thursday that it has acquired Blue Fin Group, a full-service professional management consulting firm delivering research, strategy, and implementation services to help manufacturers optimize access. More than 300 Life Sciences manufacturers – spanning cell and gene therapies, orphan/rare, specialty, primary care, vaccines, biosimilars, and generics – have relied on Blue Fin Group to optimize patient outcomes by orchestrating marketing, market access, field sales, pharmacy and distribution, and patient services as a seamless commercial strategy.

TriNetX Acquires Pharmacovigilance Leader Advera Health Analytics

TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, today announced the acquisition of Advera Health Analytics, the leader in pharmacovigilance software and data for detection, management, and mitigation of drug safety concerns. The acquisition of Advera, and its industry-leading Evidex platform, will enable TriNetX clients to gain a complete view of drug safety issues as they happen in real time. The power of Evidex, and the vast real-world data on the TriNetX network, will help life sciences companies refine, manage, and validate safety signals with deep clinical data, and greater efficiency than what the industry has traditionally relied upon.

Three Companies Join Forces to Become Centricity Research, North America’s Largest lntegrated Research Site Organization

Clinical research leaders IACT Health, LMC Manna Research and True North Clinical Research — which joined forces last month — today proudly announced their new name is Centricity Research. What began in November 2021 as a strategic alliance between Columbus, Georgia-based IACT Health and Toronto, Ontario-based LMC Manna Research continued with the merger of True North Clinical Research in December of 2021. These integrations – under the new company name Centricity Research – have created the largest consolidated research network across North America. Centricity Research boasts more than 40 sites, access to over 1.6 million patients, and more than 150 active investigators.

Publicis Health Acquires BBK Worldwide

Publicis Health, the health and wellness vertical of Publicis Groupe, announced Tuesday the acquisition of BBK Worldwide (BBK), a full-service R&D marketing firm and a global leader in clinical trial experience (CTE). BBK enables biotech and pharmaceutical customers to accelerate R&D programs, driving research forward through the unique integration of patient-centric services and proprietary technology, complementing Publicis Health’s existing CTE capabilities. Founded in 1983 with a commitment to putting the patient first, BBK leverages real-world data and experience to remove barriers to clinical trial participation and increase access to care for patients.

Schrödinger Announces Acquisition of XTAL BioStructures, Inc.

Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the acquisition of XTAL BioStructures, Inc., a private company based in the Greater Boston area that provides structural biology services, including biophysical methods, protein production and purification, and X-ray crystallography, to the pharmaceutical and biotechnology industries.

San Diego Cell Therapy CDMO Acquired by Healthcare-Focused Private Equity Firm

Performance Cell Manufacturing (“PCM”), a contract development and manufacturing organization (“CDMO”) with more than 15 years of experience in manufacturing cell therapies, announced that it has been acquired by Great Point Partners (“GPP”), a Greenwich, Connecticut based private investment firm focused on the healthcare industry. As part of the transaction, the company also announced that it will operate under a new name: Cellipont Bioservices. This is the latest in a series of CDMO investments by Great Point Partners. The firm has also made investments in other CDMOs, including Cytovance Biologics, MaSTherCell, Tergus Pharma and Bionova Scientific.

Advent Weighs Options Including $1.5B BioDuro Sale

Buyout firm Advent International is considering options for its health-care company BioDuro-Sundia including a sale that could give the asset a value of at least $1.5 billion, according to people familiar with the matter. Other options being evaluated with financial advisers include an initial public offering in China, the people said, asking not to be identified because the matter is confidential. Private equity firms and industry players could be interested in acquiring the drug research, development and manufacturing business, they said. A sale could even value BioDuro-Sundia at more than $2 billion, two of the people said. BioDuro-Sundia provides large biopharmaceutical companies with services including drug discovery, development and manufacturing, according to a recent press release.

Clinical Research Technology Leader RealTime Secures Growth Investment from LLR Partners

RealTime Software Solutions, LLC, a leader in cloud-based software solutions for the clinical research industry, today announced a significant growth investment from LLR Partners. The capital and resources from this partnership will be dedicated to helping accelerate the company’s growth, product innovation and delivery of world-class customer experiences.RealTime is dedicated to solving problems and providing systems that make the clinical research process more efficient and compliant. The company’s complete Site Operations Management System (SOMS) enables research sites to run better, recruit faster and perform higher.

Flourish Research Adds Great Lakes Clinical Trials and Clinical Site Partners to the Network

Flourish Research announced today the addition of Great Lakes Clinical Trials (“Great Lakes”) and Clinical Site Partners (“CSP”) to its growing network. These leading clinical trial sites join Clinical Trials of Texas, LLC (“CTT”), which is the platform site for the network, and Excel Medical Clinical Trials, which joined Flourish in October. CSP was founded in 2003 by leading pulmonologist Dr. Faisal A. Fakih, and Co-Founder Ana Marquez. It has since expanded to three sites located throughout Florida, allowing it access to the state’s diverse population. Founded in 2013 by industry veteran, Steve Satek, Great Lakes is a diversified site network with four locations throughout the Chicago area.

Susquehanna Private Capital Announces Investment in Spherix Global Insights

Susquehanna Private Capital (“SPC”), a middle market private equity firm, announced Tuesday an investment in Spherix Global Insights (“Spherix” or the “Company”), a leading pharmaceutical market insights firm focused on the dermatology, gastroenterology, nephrology, neurology, ophthalmology, and rheumatology specialties. Founded in 2015 by Jennifer and Kevin Robinson, Spherix provides pharmaceutical market insights and intelligence through its proprietary network of over 3,000 active specialty providers and their patients.